These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33662279)

  • 21. Hitting KRAS When It's Down.
    Gabizon R; London N
    J Med Chem; 2020 Jul; 63(13):6677-6678. PubMed ID: 32568546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of two G-quadruplexes in equilibrium in the KRAS promoter.
    Marquevielle J; Robert C; Lagrabette O; Wahid M; Bourdoncle A; Xodo LE; Mergny JL; Salgado GF
    Nucleic Acids Res; 2020 Sep; 48(16):9336-9345. PubMed ID: 32432667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dueling KRAS
    Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial strategies to target RAS-driven cancers.
    Perurena N; Situ L; Cichowski K
    Nat Rev Cancer; 2024 May; 24(5):316-337. PubMed ID: 38627557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a Covalent Inhibitor of KRAS
    Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
    J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting cancer with molecular glues.
    Liu JO
    Science; 2023 Aug; 381(6659):729-730. PubMed ID: 37590349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutated RAS: Targeting the "Untargetable" with T Cells.
    Chatani PD; Yang JC
    Clin Cancer Res; 2020 Feb; 26(3):537-544. PubMed ID: 31511296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting.
    Shu L; Wang D; Saba NF; Chen ZG
    Mol Cancer Ther; 2020 Apr; 19(4):999-1007. PubMed ID: 32241873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct Ras G12C inhibitors: crossing the rubicon.
    Lindsay CR; Blackhall FH
    Br J Cancer; 2019 Jul; 121(3):197-198. PubMed ID: 31239544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches to inhibiting oncogenic K-Ras.
    Gorfe AA; Cho KJ
    Small GTPases; 2021 Mar; 12(2):96-105. PubMed ID: 31438765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
    Ushijima T; Yoshino T
    Cancer Res; 2016 Nov; 76(22):6443-6444. PubMed ID: 28148677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.